For research use only. Not for therapeutic Use.
Clofazimine(Cat No.:A000925)is an antimicrobial agent primarily used to treat leprosy, particularly in multidrug therapy to combat Mycobacterium leprae. It has anti-inflammatory properties, making it useful for managing leprosy reactions and reducing painful inflammation in affected tissues. Clofazimine accumulates in bacterial cells, binding to bacterial DNA and disrupting replication and cellular processes. It is also effective against certain non-tuberculous mycobacterial infections, including Mycobacterium avium complex. Its distinctive pigmentation effect, causing skin discoloration, is a common side effect but does not limit its critical role in leprosy treatment.
Catalog Number | A000925 |
CAS Number | 2030-63-9 |
Synonyms | 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina |
Molecular Formula | C27H22Cl2N4 |
Purity | ≥95% |
Target | Cell Cycle/DNA Damage |
Storage | -20°C |
Reference | 1: Lin J, Lin Z, Li D, Feng M, Yang Q, Hu W, Han Y, Zhu W, Li M, Yu L. /Ghost 2: Maartens G, Brill MJE, Pandie M, Svensson EM. Pharmacokinetic interaction <br> 4: Yew WW, Liang D, Chan DP, Shi W, Zhang Y. Molecular mechanisms of clofazimine 5: Tuvshintulga B, AbouLaila M, Sivakumar T, Tayebwa DS, Gantuya S, Naranbaatar 6: Brunaugh AD, Jan SU, Ferrati S, Smyth HDC. Excipient-Free Pulmonary Delivery 7: Murashov MD, LaLone V, Rzeczycki PM, Keswani RK, Yoon GS, Sud S, Rajeswaran W, 8: Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, 9: Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of Clinical Drug Interaction 10: Makgatho EM, Mbajiorgu EF. In vitro investigation of clofazimine analogues |